ICR Expands into Asia Pacific with PACRA
The Institute of Clinical Research (ICR) has signed a significant new partnership agreement to provide research and training to clinical research professionals throughout the Asia Pacific region.
The collaboration with the Pan-Asian Clinical Research Association (PACRA) will expand the ICR’s global presence in the Far East and add new training resources to PACRA members.
Dr Paul Wathall, interim chief executive of the ICR, commented: "We're delighted to be working with PACRA on such an exciting project. ”
PACRA was established earlier this year and aims to promote clinical research training and continuing professional development for clinical researchers in Asia. It provides current information, news and topical articles along with a range of special features for clinical research professionals across the region.
As part of the agreement the ICR’s members’ journal CRfocus will be produced quarterly and rebranded as ‘Silk Route’ for the Asia Pacific members via the PACRA website. Joint members will benefit from discounted ICR learning resources and training courses.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
